Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new ...
GlobalData on MSN
Natera demonstrates MRD test benefit in colorectal cancer patients
Ahead of the study's publication, the data was shared at the 2026 European Society for Medical Oncology Gastrointestinal ...
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...
Medical Device Network on MSN
Quest Diagnostics’ Haystack MRD test secures NYSDOH approval
The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National ...
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack ...
Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its ...
(RTTNews) - Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) ...
Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...
Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results